Renal Denervation Downer: Medtronic’s Pivotal Trial Misses Efficacy Endpoint
This article was originally published in The Pink Sheet Daily
The firm’s SYMPLICITY HTN-3 trial failed to meet its primary efficacy endpoint, scuttling Medtronic’s plans to earn a PMA for renal denervation this year. The primary investigator for the trial acknowledges in an interview that the finding raises serious questions for the future of renal denervation in hypertension.
You may also be interested in...
Drug-coated balloons have emerged as one of the next major product segments within interventional cardiology, particularly for the treatment of peripheral arterial disease. But a recent recall from Medtronic based on clinical trial data could temper enthusiasm for using the technology below the knee in patients with critical limb ischemia.
Patient-recruitment challenges have led St. Jude to halt a U.S. clinical trial of its EnligHTN renal denervation system. The company says it is working with FDA to design a new trial.
Medtronic Renal Denervation System Provides Durable Blood Pressure Benefits In Longest Trial To Date
The latest results from Medtronic’s SYMPLICITY HTN-2 trial show that patients treated for severe hypertension with the company’s Symplicity radio frequency renal denervation system showed a sustained reduction in blood pressure. The firm also announced the start of a renal denervation trial in patients with moderate hypertension.